Eiger BioPharmaceuticals, Inc. (EIGR) Given Average Rating of “Buy” by Analysts
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has been given a consensus rating of “Buy” by the six brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $32.60.
Several analysts have weighed in on EIGR shares. Wedbush reiterated an “outperform” rating and issued a $34.00 price objective (up previously from $28.00) on shares of Eiger BioPharmaceuticals in a research report on Wednesday, June 21st. Oppenheimer Holdings, Inc. set a $34.00 price objective on Eiger BioPharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 10th. Zacks Investment Research downgraded Eiger BioPharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $27.00 price objective (down previously from $28.00) on shares of Eiger BioPharmaceuticals in a research report on Monday, May 15th. Finally, BTIG Research started coverage on Eiger BioPharmaceuticals in a research report on Friday, July 14th. They issued a “buy” rating and a $32.00 price objective for the company.
Several institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its position in shares of Eiger BioPharmaceuticals by 6.4% in the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after buying an additional 871 shares in the last quarter. LMR Partners LLP acquired a new position in shares of Eiger BioPharmaceuticals during the second quarter worth approximately $116,000. Finally, Hikari Power Ltd acquired a new position in shares of Eiger BioPharmaceuticals during the first quarter worth approximately $118,000. Institutional investors own 68.86% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/eiger-biopharmaceuticals-inc-eigr-given-average-rating-of-buy-by-analysts.html.
Shares of Eiger BioPharmaceuticals (NASDAQ EIGR) opened at 8.25 on Tuesday. The firm has a 50-day moving average of $7.96 and a 200-day moving average of $9.22. Eiger BioPharmaceuticals has a one year low of $6.10 and a one year high of $20.18. The company’s market capitalization is $69.03 million.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings data on Friday, May 12th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.35) by $0.01. Equities research analysts expect that Eiger BioPharmaceuticals will post ($5.40) EPS for the current fiscal year.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.